CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results